Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 4/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 3/20 | 0.33 |
| ▸ | MTHFD2 | P13995 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | PRLHR | P49683 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22615328 | 0.86 | GSK3B (0.37) | CHRNA7CFTRMTHFD2PRLHR | |
| SCHEMBL22615211 | 0.86 | GSK3B (0.37) | CHRNA7CFTRMTHFD2PRLHR | |
| SCHEMBL22615213 | 0.86 | GSK3B (0.37) | CHRNA7CFTRMTHFD2PRLHR | |
| SCHEMBL22615335 | 0.84 | DDR1 (0.34) | CHRNA7EP300CREBBPCFTRMTHFD2 | |
| SCHEMBL22615242 | 0.84 | CHRNA7 (0.35) | CHRNA7EP300CREBBPCFTRMTHFD2 | |
| SCHEMBL22615579 | 0.83 | MTHFD2 (0.40) | CHRNA7CFTRMTHFD2 | |
| SCHEMBL22615301 | 0.83 | CHRNA7 (0.33) | CHRNA7CFTRMTHFD2GRM5 | |
| SCHEMBL22615322 | 0.81 | CHRNA7 (0.34) | CHRNA7MTHFD2PRLHR | |
| SCHEMBL22615401 | 0.79 | AURKA (0.39) | EP300CREBBPMTHFD2 | |
| SCHEMBL22615482 | 0.79 | NAMPT (0.38) | CHRNA7MTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227789-A1 | NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-07-21 | — | — | US | disclosed |
| EP-3962913-A1 | NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020221824-A1 | NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020221824-A1 | NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227789-A1 | NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, BRD4 | CHRNA7 4715/4885EP300 1008/4885CREBBP 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.